Skip to main content

Nivolumab + Ipilimumab

Combination dosing guide#


1L metastatic/recurrent NSCLC (with chemo)

 


1L metastatic/recurrent NSCLC*

 


1L unresectable malignant pleural mesothelioma

 


1L advanced ccRCC**

 


2L+ advanced HCC

 


Metastatic/unresectable melanoma

 


2L+ MSI-H/d-MMR metastatic/recurrent CRC

 


1L unresectable advanced/ recurrent/metastatic ESCC

#This guide is for scientific education purposes only in response to your enquires/request. For further enquiries, please contact your local BMS Medical Science Liaison or contact BMS Medical Information Department at medinfo.hongkong@bms.com.

*These indications are not yet approved in Hong Kong; this information is based on FDA-approved indications. Please refer to the Hong Kong prescribing information for the latest status.

**Nivolumab in combination with ipilimumab is only approved for 1L ccRCC patients with an intermediate or poor risk profile.

1L, first-line; 2L+, second-line or later; ccRCC, clear cell renal cell carcinoma; CRC, colorectal cancer; d-MMR, mismatch repair deficient; ESCC, esophageal squamous cell carcinoma; FDA, US Food and Drug Administration; HCC, hepatocellular carcinoma; MSI-H, high microsatellite instability; NSCLC, non-small cell lung cancer.